Huge Part Of Potential Patient Pool Excluded In Aduhelm Clinical Trials
A study found as many as 92% of Medicare beneficiaries, who'd comprise a key portion of potential patients, would have been excluded from Biogen's Alzheimer's drug trials. Meanwhile, an analysis of drug labeling says a third of the uses for cancer drugs stay on labels after being unconfirmed.